Is Regentis Biomaterials Ltd. (RGNT) a Buy, Sell, or Hold?
Regentis Biomaterials Ltd.
AMEX:RGNT
$2.501 USD
-$0.97 (-27.93%)
- Volume
- 247.96K
- Average Volume
- 5.37M
- Market Capitalization
- $9.85M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- $
- Year High
- $15.50
- Year Low
- $1.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $
- Current Ratio
- $
Industry, Sector & symbol
| Stock Exchange | AMEX |
| CEO | Ehud Geller |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Current Symbol | RGNT |
| CUSIP | 001219096 |
| CIK | 0001912966 |
| Web | https://www.regentis.co.il |
| Phone | 972 9 960 1917 |
| Currency | USD |
| Employees | 10 |
| Country | IL |
Liquidity
| Debt-to-Equity Ratio | |
| Payout Ratio | |
| Current Ratio | |
| Quick Ratio | |
| Cash Ratio |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | |
| Cash Flow | |
| Price / Cash Flow | |
| Price / Book |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $ |
| Trailing P/E Ratio | |
| PEG Ratio | |
| P/E Growth | |
| Net Income | $- |
| Net Margin | % |
| Pretax Margin | % |
| Return on Equity | % |
| Return on Assets | % |
Financials Score
| AltmanZ Score | |
| Piotroski Score | |
| Working Capital | - |
| Total Assets | - |
| Ebit | - |
| Market Cap | - |
| Total Liabilities | - |
Poll Results
About Regentis Biomaterials Ltd. (AMEX:RGNT) Stock
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel. ...
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
2026-06-17 21:05:00
HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or pre-funded warrants in lieu thereof) together with warrants , at a purchase price of $3.50 per ordinary share and accompanying ordinary warrant (or $3.4999 per pre-funded warrant and accompanying ordinary warrant), in a private placement, for expected aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and estimated offering expenses payable by us.
2026-06-08 08:32:00
GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union Regentis is growing its network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinC GelrinC's 10-minute procedure offers a safe and effective alternative to traditional microfracture and complex cell-based therapies addressing a $3 billion U.S. market HERZLIYA, ISRAEL / ACCESS Newswire / June 8, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC® in Europe, where it has CE Mark approval.
2026-04-16 08:30:00
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption Renowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence network Strengthens surgeon engagement and expands Regentis' European commercialization infrastructure HERZLIYA, IL / ACCESS Newswire / April 16, 2026 / Regentis Biomaterials Ltd.
Frequently Asked Questions
-
What is the current Regentis Biomaterials Ltd. (RGNT) stock price?
-
Regentis Biomaterials Ltd.(AMEX:RGNT) stock price is $2.501 in the last trading session. During the trading session, RGNT stock reached the peak price of $15.5 while $1.232 was the lowest point it dropped to. The percentage change in RGNT stock occurred in the recent session was --27.93% while the dollar amount for the price change in RGNT stock was -$-0.97.
-
RGNT's industry and sector of operation?
-
The AMEX listed RGNT is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of RGNT?
-
Dror Seliktar | Co-Founder & Chief Scientific Officer
Ehud Geller | CEO & Executive Chairman
Arie Gordashnikov | Chief Accounting Officer
Ori Gon | CFO & Chief Business Officer
Galit Reske | Chief Medical Officer -
How many employees does RGNT have?
-
Number of RGNT employees currently stands at 10. RGNT operates from 60 Medinat Hayehudim Street, Herzliya, TA 4676652, IL.
-
Link for RGNT official website?
-
Official Website of RGNT is: https://www.regentis.co.il
-
How do I contact RGNT?
-
RGNT could be contacted at phone #972 9 960 1917 and can also be accessed through its website. RGNT operates from 60 Medinat Hayehudim Street, Herzliya, TA 4676652, IL.
-
How many shares of RGNT are traded daily?
-
The average number of RGNT shares traded daily for last 3 months was 5.37M.
-
What is the market cap of RGNT currently?
-
The market value of RGNT currently stands at $9.85M with its latest stock price at $2.501